查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1556750

蜂群刺激因子市場報告：2030 年趨勢、預測與競爭分析

Colony Stimulating Factor Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

集落刺激因子的趨勢和預測

到 2030 年，全球菌落刺激因子市場預計將達到 137 億美元，2024 年至 2030 年複合年成長率為 10.4%。該市場的主要促進因素是癌症和血液疾病盛行率的增加、創新療法研發投資的增加以及對先進癌症治療的需求不斷成長。全球集落刺激因子市場的未來充滿希望，醫院、專科診所和居家醫療市場都有機會。

按細分市場分類的集落刺激因子

本研究包括按類型、施用方法、應用、最終用途和區域對全球集落刺激因子進行預測。

集落刺激因子市場洞察

Lucintel 預測，注射劑將在預測期內達到最高成長。

在這個市場中，由於擴大採用居家醫療作為降低醫療保健成本和改善患者治療效果的一種方式，居家醫療預計將顯示出最高的成長。

由於人口癌症發病率不斷上升以及該地區擁有強大的醫療保健系統，預計北美在預測期內仍將是最大的地區。

常問問題

Q1.市場規模為：

A1. 到 2030 年，全球菌落刺激因子市場預計將達到 137 億美元。

Q2.市場成長預測是多少：

A2. 2024 年至 2030 年，全球集落刺激因子市場預計將以 10.4% 的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3. 該市場的主要驅動力是癌症和血液疾病盛行率的增加、創新療法研發投資的增加以及對先進癌症治療的需求不斷成長。

Q4.市場的主要細分市場是：

A4. 集落刺激因子市場前景廣闊，在醫院、專科診所和居家醫療市場都有機會。

Q5.市場的主要企業是：

A5. 主要的集落刺激因子公司如下：

  • Intas Pharmaceuticals
  • Sanofi
  • Novartis
  • Teva Pharmaceutical Industries
  • Pfizer
  • GlaxoSmithKline
  • Biocon
  • Dr. Reddy's Laboratories
  • Amgen
  • Merck

Q6.未來最大的細分市場是什麼？

A6.Lucintel預測，注射劑將在預測期內出現最高成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於人口癌症發生率不斷上升以及該地區擁有強大的醫療保健系統，北美在預測期內仍將是最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章 全球集落刺激因子市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球菌落刺激因子市場趨勢（2018-2023）與預測（2024-2030）
  • 全球集落刺激因子市場（按類型）
    • 巨噬細胞集落刺激因子
    • 多種集落刺激因子或白細胞介素3
    • 粒細胞-巨噬細胞集落刺激因子
    • 顆粒細胞增生因子
  • 按管理方法分類的全球集落刺激因子市場
    • 注射
    • 藥片
    • 膠囊
    • 其他
  • 按應用分類的集落刺激因子的全球市場
    • 再生障礙性貧血
    • 骨髓移植
    • 嗜中性白血球低下症
    • 化療相關的嗜中性白血球低下症
    • 放射線相關的嗜中性白血球低下症
    • 周邊血幹細胞移植
  • 以最終用途分類的全球集落刺激因子市場
    • 醫院
    • 專科診所
    • 居家醫療
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球集落刺激因子市場（按地區）
  • 北美集落刺激因子市場
  • 歐洲集落刺激因子市場
  • 亞太集落刺激因子市場
  • 其他地區集落刺激因子市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球集落刺激因子市場類型的成長機會
    • 按管理方法分類的全球菌落刺激因子市場成長機會
    • 全球菌落刺激因子市場成長機會（按應用）
    • 全球菌落刺激因素市場成長機會（依最終用途）
    • 全球菌落刺激因素市場成長機會（按地區）
  • 全球集落刺激因子市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球集落刺激因子市場產能擴張
    • 全球集落刺激因子市場的合併、收購與合資企業
    • 認證和許可

第7章主要企業概況

  • Intas Pharmaceuticals
  • Sanofi
  • Novartis
  • Teva Pharmaceutical Industries
  • Pfizer
  • GlaxoSmithKline
  • Biocon
  • Dr. Reddy's Laboratories
  • Amgen
  • Merck
簡介目錄

Colony Stimulating Factor Trends and Forecast

The future of the global colony stimulating factor market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global colony stimulating factor market is expected to reach an estimated $13.7 billion by 2030 with a CAGR of 10.4% from 2024 to 2030. The major drivers for this market are increasing prevalence of cancer and hematological diseases, rising investments in research and development for innovative treatments, and growing demand for advanced cancer therapies.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Colony Stimulating Factor by Segment

The study includes a forecast for the global colony stimulating factor by type, dosage, application, end use, and region.

Colony Stimulating Factor Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Macrophage-Colony-Stimulating Factor
  • Multiple-Colony-Stimulating Factor or Interleukin 3
  • Granulocyte-Macrophage-Colony-Stimulating Factor
  • Granulocyte-Colony-Stimulating Factor

Colony Stimulating Factor Market by Dosage [Shipment Analysis by Value from 2018 to 2030]:

  • Injection
  • Tablets
  • Capsule
  • Others

Colony Stimulating Factor Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Aplastic Anemia
  • Bone Marrow Transplantation
  • Neutropenia
  • Neutropenia Associated With Chemotherapy
  • Neutropenia Associated With Radiation
  • Peripheral Progenitor Cell Transplantation

Colony Stimulating Factor Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Colony Stimulating Factor Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Colony Stimulating Factor Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies colony stimulating factor companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the colony stimulating factor companies profiled in this report include-

  • Intas Pharmaceuticals
  • Sanofi
  • Novartis
  • Teva Pharmaceutical Industries
  • Pfizer
  • GlaxoSmithKline
  • Biocon
  • Dr. Reddy's Laboratories
  • Amgen
  • Merck

Colony Stimulating Factor Market Insights

Lucintel forecasts that injection is expected to witness the highest growth over the forecast period.

Within this market, homecare is expected to witness the highest growth due to increasing adoption for homecare as a way to reduce healthcare costs and improve patient outcomes.

North America will remain the largest region over the forecast period due to increasing incidence of cancer among population and existence of robust healthcare system in the region.

Features of the Global Colony Stimulating Factor Market

Market Size Estimates: Colony stimulating factor market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Colony stimulating factor market size by various segments, such as by type, dosage, application, end use, and region in terms of value ($B).

Regional Analysis: Colony stimulating factor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, dosages, applications, end uses, and regions for the colony stimulating factor market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the colony stimulating factor market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the colony stimulating factor market size?

Answer: The global colony stimulating factor market is expected to reach an estimated $13.7 billion by 2030.

Q2. What is the growth forecast for colony stimulating factor market?

Answer: The global colony stimulating factor market is expected to grow with a CAGR of 10.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the colony stimulating factor market?

Answer: The major drivers for this market are increasing prevalence of cancer and hematological diseases, rising investments in research and development for innovative treatments, and growing demand for advanced cancer therapies.

Q4. What are the major segments for colony stimulating factor market?

Answer: The future of the colony stimulating factor market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q5. Who are the key colony stimulating factor market companies?

Answer: Some of the key colony stimulating factor companies are as follows:

  • Intas Pharmaceuticals
  • Sanofi
  • Novartis
  • Teva Pharmaceutical Industries
  • Pfizer
  • GlaxoSmithKline
  • Biocon
  • Dr. Reddy's Laboratories
  • Amgen
  • Merck

Q6. Which colony stimulating factor market segment will be the largest in future?

Answer: Lucintel forecasts that injection is expected to witness the highest growth over the forecast period.

Q7. In colony stimulating factor market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing incidence of cancer among population and existence of robust healthcare system in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the colony stimulating factor market by type (macrophage-colony-stimulating factor, multiple-colony-stimulating factor or interleukin 3, granulocyte-macrophage-colony-stimulating factor, and granulocyte-colony-stimulating factor), dosage (injection, tablets, capsule, and others), application (aplastic anemia, bone marrow transplantation, neutropenia, neutropenia associated with chemotherapy, neutropenia associated with radiation, and peripheral progenitor cell transplantation), end use (hospitals, specialty clinics, homecare, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Colony Stimulating Factor Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Colony Stimulating Factor Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Colony Stimulating Factor Market by Type
    • 3.3.1: Macrophage-Colony-Stimulating Factor
    • 3.3.2: Multiple-Colony-Stimulating Factor or Interleukin 3
    • 3.3.3: Granulocyte-Macrophage-Colony-Stimulating Factor
    • 3.3.4: Granulocyte-Colony-Stimulating Factor
  • 3.4: Global Colony Stimulating Factor Market by Dosage
    • 3.4.1: Injection
    • 3.4.2: Tablets
    • 3.4.3: Capsule
    • 3.4.4: Others
  • 3.5: Global Colony Stimulating Factor Market by Application
    • 3.5.1: Aplastic Anemia
    • 3.5.2: Bone Marrow Transplantation
    • 3.5.3: Neutropenia
    • 3.5.4: Neutropenia Associated with Chemotherapy
    • 3.5.5: Neutropenia Associated with Radiation
    • 3.5.6: Peripheral Progenitor Cell Transplantation
  • 3.6: Global Colony Stimulating Factor Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Specialty Clinics
    • 3.6.3: Homecare
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Colony Stimulating Factor Market by Region
  • 4.2: North American Colony Stimulating Factor Market
    • 4.2.1: North American Colony Stimulating Factor Market by Dosage: Injection, Tablets, Capsule, and Others
    • 4.2.2: North American Colony Stimulating Factor Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.3: European Colony Stimulating Factor Market
    • 4.3.1: European Colony Stimulating Factor Market by Dosage: Injection, Tablets, Capsule, and Others
    • 4.3.2: European Colony Stimulating Factor Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.4: APAC Colony Stimulating Factor Market
    • 4.4.1: APAC Colony Stimulating Factor Market by Dosage: Injection, Tablets, Capsule, and Others
    • 4.4.2: APAC Colony Stimulating Factor Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.5: ROW Colony Stimulating Factor Market
    • 4.5.1: ROW Colony Stimulating Factor Market by Dosage: Injection, Tablets, Capsule, and Others
    • 4.5.2: ROW Colony Stimulating Factor Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Colony Stimulating Factor Market by Type
    • 6.1.2: Growth Opportunities for the Global Colony Stimulating Factor Market by Dosage
    • 6.1.3: Growth Opportunities for the Global Colony Stimulating Factor Market by Application
    • 6.1.4: Growth Opportunities for the Global Colony Stimulating Factor Market by End Use
    • 6.1.5: Growth Opportunities for the Global Colony Stimulating Factor Market by Region
  • 6.2: Emerging Trends in the Global Colony Stimulating Factor Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Colony Stimulating Factor Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Colony Stimulating Factor Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Intas Pharmaceuticals
  • 7.2: Sanofi
  • 7.3: Novartis
  • 7.4: Teva Pharmaceutical Industries
  • 7.5: Pfizer
  • 7.6: GlaxoSmithKline
  • 7.7: Biocon
  • 7.8: Dr. Reddy's Laboratories
  • 7.9: Amgen
  • 7.10: Merck